evipedia.aidev
← Back

Progesterone for Health & Longevity

Evidence Review created on 08/04/2026 using AI4L / Opus 5

Also known as: Micronized Progesterone, Oral Micronized Progesterone, Bioidentical Progesterone, Natural Progesterone, Prometrium, Utrogestan, P4

Motivation

Progesterone is one of the two main hormones made by the ovaries. It rises after each egg release, falls away in the years around the last menstrual period, and is also produced in smaller amounts by the adrenal glands in both sexes. The body-identical hormone sold as capsules, gels, and creams is the same molecule the body makes, which sets it apart from the synthetic look-alikes used in most birth control and in older hormone therapy.

For decades the two were treated as interchangeable, and findings from studies of the synthetic versions were widely read as applying to both. A separate line of work has since asked whether the body-identical hormone behaves differently — in the lining of the uterus, in breast tissue, and in sleep — and whether the answer changes how the risks and benefits of hormone therapy should be weighed.

This review examines what the evidence shows about taking progesterone with health and longevity in mind: what it does in the body, which effects hold up in controlled human studies, which remain uncertain, what the drawbacks are, and how it is dosed, timed, sourced, and monitored in practice.

Benefits - Risks - Protocol - Conclusion

A short list of high-quality overviews from clinicians and researchers who discuss progesterone therapy directly.

No item from Rhonda Patrick (foundmyfitness.com) is included: a direct site search returns only brief research summaries that mention progesterone in passing and members-only question-and-answer segments on hormone therapy timing, none of which treats progesterone itself in the depth required here.

Grokipedia

Progesterone

A dense reference entry covering the hormone’s biosynthesis from cholesterol, its receptor biology, and its pharmacology. It is useful for orienting on nomenclature and metabolism before reading the clinical literature.

Examine

Progesterone

Examine’s dedicated progesterone page catalogues which dietary supplements have been tested for their effect on circulating progesterone levels, with graded evidence for coenzyme Q10, maca, chromium, and others. It is relevant here as a check on whether progesterone can be raised without prescribing it, and the answer it documents is largely no.

ConsumerLab

Menopause Supplements Review (Soy and Red Clover Isoflavones, Black Cohosh) and Progesterone Creams

Reports independent laboratory testing of over-the-counter progesterone creams, which were found to contain the amounts claimed, alongside the observation that cream doses do not deliver enough hormone to preserve bone density. Prescription capsules are outside ConsumerLab’s testing remit, so the report speaks only to the over-the-counter segment.

Systematic Reviews

The following systematic reviews and meta-analyses address progesterone across the outcomes most relevant to long-term use.

  • Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data - Nolan et al., 2021

    Pools nine randomized controlled trials (RCTs — studies in which participants are randomly assigned to treatment or placebo) covering 388 participants and finds a consistent benefit for time to fall asleep but inconsistent effects on total sleep time. It is the strongest quantitative evidence for the sleep claim and is candid about the small trial sizes.

  • The impact of micronized progesterone on the endometrium: a systematic review - Stute et al., 2016

    Establishes the dose, duration, and route needed to protect the uterine lining during estrogen therapy, and is the source of the finding that transdermal progesterone does not protect it at all. The review was produced by an expert panel convened around Climacteric, the journal of the International Menopause Society — a professional body whose members prescribe hormone therapy and whose meetings draw manufacturer support — so its recommendations carry a structural interest in favourable conclusions.

  • The impact of micronized progesterone on breast cancer risk: a systematic review - Stute et al., 2018

    Concludes that combined therapy using micronized progesterone does not raise breast cancer risk for up to five years, with limited evidence of increased risk beyond that. Same expert panel and same professional-society interest as the endometrial review above, which is worth weighing against the reassurance the conclusions offer.

  • The impact of micronized progesterone on cardiovascular events - a systematic review - Kaemmle et al., 2022

    Reviews twelve studies on clots, heart attack, and stroke and finds a neutral vascular signal for micronized progesterone in combined therapy, while stating plainly that no trial has used a hard cardiovascular endpoint as its primary outcome. Also from the same menopause-society-affiliated group.

  • Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review - Coquoz et al., 2019

    Addresses the common concern that hormone therapy causes weight gain, finding no adverse effect on weight, body mass index, or blood sugar control, while attributing most of the observed benefit to the estrogen component rather than to progesterone. It comes from the same Bern group publishing through Climacteric, whose International Menopause Society membership earns its income from prescribing this therapy, so the same structural interest applies here as to the reviews above.

Mechanism of Action

Progesterone is a 21-carbon steroid built from cholesterol by way of pregnenolone. It acts through two distinct routes, and the split explains why its effects on the uterus and its effects on the brain follow completely different rules.

The classical route is the progesterone receptor, a protein inside the cell nucleus that switches genes on and off. In the endometrium (the lining of the uterus), estrogen drives proliferation; progesterone binding to its receptor halts that proliferation, converts the tissue to a secretory state, and triggers orderly shedding when levels fall. This antagonism is the entire basis for using progesterone alongside estrogen therapy. The same receptor mediates its actions in breast tissue and bone, where it opposes estrogen in some compartments and cooperates with it in others.

The second route is neurosteroid activity by its metabolites, chiefly allopregnanolone. The enzymes 5α-reductase and 3α-hydroxysteroid dehydrogenase convert progesterone into allopregnanolone, which is a positive allosteric modulator of the GABA-A receptor (the brain’s principal calming, or inhibitory, receptor — the same one acted on by benzodiazepines, a class of sedative and anti-anxiety medications, and by alcohol). This is not receptor-mediated in the classical sense at all, and it accounts for the sedation, the sleep effects, and the mood effects, including the paradoxical low mood some people experience. Progesterone also weakly blocks the mineralocorticoid receptor (which controls sodium and fluid retention), which is why it does not cause the fluid retention seen with some synthetic progestins.

Two competing mechanistic accounts sit behind the debate over long-term use. The first holds that progesterone’s role is essentially permissive — its job is to protect the uterine lining, and any systemic effect is incidental or mildly unfavourable, so the lowest effective dose for the shortest necessary time is the rational approach. The second, argued most forcefully from menstrual-cycle research, holds that progesterone is an independent physiological actor whose absence during years of disturbed ovulation contributes to bone loss and vascular change, so restoring it has value in its own right. Both accounts fit the receptor biology; they diverge on how much weight to give the non-uterine actions.

Key pharmacological properties of the oral micronized form:

  • Bioavailability: low. Micronization (grinding to very fine particles) was developed specifically because unmodified progesterone is almost entirely destroyed before reaching the circulation; even micronized, most of an oral dose is metabolized on first pass through the liver.
  • Half-life: blood levels peak roughly 1–3 hours after an oral dose and fall steeply afterwards, with reported elimination half-lives in the range of several hours to about 18 hours depending on the metabolite measured. The short peak is why bedtime dosing produces the sleep effect without daytime sedation.
  • Selectivity: high affinity for the progesterone receptor, modest antimineralocorticoid and antiandrogenic activity, and essentially no glucocorticoid or androgenic activity — a cleaner profile than medroxyprogesterone acetate (MPA, the synthetic progestin used in most older hormone therapy trials) or the 19-nortestosterone-derived progestins (a synthetic progestin family built on a modified testosterone skeleton, which is why they retain some male-hormone-like activity).
  • Tissue distribution: widely distributed and lipophilic (fat-soluble), with high concentrations in fat tissue and brain. Vaginal dosing produces a uterine first-pass effect: endometrial tissue concentrations far exceed what the corresponding blood level would predict.
  • Metabolism: hepatic, via 5α- and 5β-reductases and 3α- and 20α-hydroxysteroid dehydrogenases to allopregnanolone and pregnanolone, with CYP3A4 (a major liver drug-metabolizing enzyme) contributing hydroxylated metabolites. Conjugated metabolites are excreted mainly in urine as pregnanediol glucuronide.

Historical Context & Evolution

  • Original purpose: Progesterone was isolated in 1934 and first used to sustain pregnancy and treat menstrual disorders. Its supply problem was solved in the 1940s when Russell Marker converted diosgenin from Mexican yam into progesterone, making the hormone cheap and abundant for the first time.
  • Displacement by synthetics: Because oral progesterone was destroyed by the liver, the pharmaceutical industry built modified molecules — progestins — that survived oral dosing and could be patented. Medroxyprogesterone acetate and the 19-nortestosterone derivatives became the default, and for roughly forty years “progesterone” and “progestin” were used interchangeably in clinical writing.
  • The route back: Micronization in the 1980s made oral progesterone viable, and it was approved in the United States in 1998. Its re-entry coincided with the growth of a bioidentical hormone movement, which brought both legitimate physiology and considerable commercial promotion of compounded creams.
  • What the landmark trials actually tested: The Women’s Health Initiative, whose 2002 result reshaped hormone prescribing worldwide, used conjugated equine estrogens with medroxyprogesterone acetate. It did not test progesterone. The finding of increased breast cancer in the combined arm is therefore a finding about that progestin in that regimen, and applying it to progesterone is an extrapolation, not a result.
  • What changed the picture afterwards: Two developments moved the debate. Large French cohort data reported that estrogen combined with progesterone carried a different breast cancer signal from estrogen combined with other progestogens (the umbrella term covering both progesterone itself and the synthetic progestins), and case-control work on clotting found the same divergence. These are observational and cannot settle causation; they did establish that treating all progestogens as one class is no longer defensible.
  • Not a settled account: Reading the sequence as “the Women’s Health Initiative was misinterpreted and has now been corrected” overstates what has been shown, and reading it as “hormone therapy was proven harmful” ignores the progestogen distinction entirely. Neither the older nor the newer position rests on a randomized trial with hard endpoints for progesterone specifically, and that trial has not been run.
  • Whose money sits where: The parties producing the evidence have divergent interests. Menopause professional societies and their journals publish much of the favourable synthesis and depend on clinicians whose practices provide hormone therapy. Compounding pharmacies sell custom progesterone creams and lozenges at prices well above generic capsules and are not subject to the same approval requirements. Generic manufacturers compete on a low-margin approved product. Insurers and national health systems face a genuine cost asymmetry here — approved generic capsules cost a fraction of compounded preparations and of the levonorgestrel intrauterine device that can serve the same endometrial-protection purpose — which gives payers a systematic incentive to favour the cheapest covered option and to fund research consistent with it. None of these interests invalidates the underlying data, but each shapes which questions get asked.

Expected Benefits

High 🟩 🟩 🟩

Protection of the Uterine Lining During Estrogen Therapy ⚠️ Conflicted

Estrogen taken without opposition drives continuous growth of the endometrium, producing hyperplasia (overgrowth of the uterine lining, the precursor state to endometrial cancer). Oral micronized progesterone reverses that growth signal through the nuclear progesterone receptor and returns the tissue to a secretory, sheddable state. The evidence is a three-year randomized, double-masked, placebo-controlled trial in 596 postmenopausal women, reinforced by a systematic review that defined the effective dose, duration, and route — a review written by an expert panel convened around the International Menopause Society, whose member clinicians earn their income from prescribing this therapy. The critical caveat is that this protection is route-dependent: oral and, off-label, vaginal dosing work, while transdermal creams do not achieve it. The two evidence streams also diverge with duration: the randomized data show hyperplasia prevented over three years, while the largest cohort to follow cancer endpoints found more endometrial cancer in users of estrogen plus micronized progesterone than in never-users, so a tissue-endpoint result over three years is not a cancer-endpoint guarantee over a decade.

Magnitude: Over three years of estrogen alone, simple hyperplasia occurred in 27.7%, complex hyperplasia in 22.7%, and atypical hyperplasia in 11.8% of women, versus 0.8%, 0.8%, and 0% on placebo; adding 200 mg of oral micronized progesterone for the first 12 days of each 28-day cycle produced hyperplasia rates statistically indistinguishable from placebo.

Medium 🟩 🟩

Reduction of Hot Flushes and Night Sweats ⚠️ Conflicted

Progesterone alone, without estrogen, reduces vasomotor symptoms (hot flushes and night sweats), most likely through allopregnanolone’s action on the brain’s temperature-regulating circuits. A 12-week randomized placebo-controlled trial in 133 healthy early postmenopausal women found a clear benefit at 300 mg nightly. A subsequent four-month randomized trial in 189 perimenopausal women did not reach significance on its primary symptom score, though it could not exclude a clinically meaningful benefit and did show significant improvement in perceived night sweats, sleep quality, and daily life interference. The discrepancy is best explained by population and design: symptoms in perimenopause fluctuate far more than in postmenopause, and the perimenopausal trial was underpowered as a result. This matters for anyone considering progesterone as a non-estrogen option.

Magnitude: In early postmenopause the daily symptom score fell by 10.0 points on progesterone versus 4.4 on placebo, an adjusted difference of −4.3 (95% CI −6.6 to −1.9; CI = confidence interval, the range within which the true effect most plausibly lies). In perimenopause the third-month difference was −1.51 (95% CI −3.97 to 0.95), which did not exclude the minimal clinically important difference of 3.

Improved Sleep Continuity and Deep Sleep

Progesterone’s metabolite allopregnanolone enhances GABA-A signalling, and the resulting sleep effect is the most consistently reported non-uterine benefit. A meta-analysis of randomized trials found faster sleep onset, and a controlled crossover study using overnight polysomnography (a full sleep-laboratory recording) found that progesterone restored normal sleep architecture when sleep was experimentally disturbed, without altering already-good sleep. That distinction matters: the effect behaves like a physiological regulator rather than a sedative, and it does not suppress deep sleep the way conventional sleep medications do. Effects on total sleep time and sleep efficiency were inconsistent across trials.

Magnitude: Pooled across four randomized trials, sleep onset latency improved with an effect size (the size of the gap between treatment and placebo) of 7.10 (95% CI 1.30 to 12.91) favouring progesterone; in the crossover study, time awake after falling asleep was 53% lower and slow-wave sleep roughly 50% higher on 300 mg nightly than on placebo.

Breast Signal Distinct from Synthetic Progestins

The large French E3N cohort followed 80,377 postmenopausal women for an average of 8.1 postmenopausal years and found that the breast cancer signal depended on which progestogen was combined with estrogen. Mechanistic work supports the divergence: progesterone does not stimulate estrogen-driven breast cell proliferation the way several progestins do. This is observational evidence — women choosing progesterone in France differed in many ways from those taking other progestogens — and the finding of neutrality does not extend indefinitely with duration of use.

Magnitude: Relative risk (RR — the ratio of risk in treated versus untreated groups) of invasive breast cancer versus never-users was 1.00 (95% CI 0.83–1.22) for estrogen plus progesterone, 1.16 (0.94–1.43) for estrogen plus dydrogesterone, and 1.69 (1.50–1.91) for estrogen combined with other progestogens.

Neutral Clotting Risk Relative to Other Progestogens

Venous thromboembolism (a blood clot in a deep vein or the lungs) is the best-documented serious harm of oral estrogen therapy, and the progestogen chosen modifies it. A French multicentre case-control study of 271 clot cases and 610 matched controls found no association for micronized progesterone, in sharp contrast to norpregnane-derived progestins (a synthetic progestin family, such as nomegestrol and promegestone, built on a shortened progesterone-like backbone). A systematic review of twelve studies reached the same neutral conclusion — again from the International Menopause Society-affiliated group whose member clinicians derive their income from providing this therapy, which is worth weighing against the reassurance it offers. The evidence is observational and the confidence intervals are wide, so “no signal detected” is a fairer reading than “proven safe”.

Magnitude: Odds ratio (OR — the ratio of the odds of exposure in cases versus controls) for clot risk was 0.7 (95% CI 0.3–1.9) with micronized progesterone and 0.9 (0.4–2.3) with pregnane derivatives (progestins that retain the full progesterone-like backbone), versus 3.9 (1.5–10.0) with norpregnane derivatives; oral estrogen itself carried an OR of 4.2 (1.5–11.6) against transdermal estrogen’s 0.9 (0.4–2.1).

Metabolic Neutrality

A frequent objection to hormone therapy is weight gain and worsened blood sugar. A systematic review of combined therapy containing micronized progesterone found no such effect on body weight, body mass index, fasting glucose, fasting insulin, or glycated hemoglobin (HbA1c, a three-month average of blood sugar) — a review produced by the same menopause-society-affiliated group whose member clinicians derive their income from prescribing this therapy, which is worth weighing against the reassurance it offers. The review attributes most of the favourable metabolic signal to estrogen rather than to progesterone, so the accurate claim is that progesterone does not undo estrogen’s metabolic benefit, not that it produces one.

Magnitude: Across the reviewed studies, regimens containing micronized progesterone left body weight unchanged or slightly reduced and body mass index unchanged in normal-weight and overweight postmenopausal women, with fasting glucose and insulin unchanged or improved in both diabetic and non-diabetic women.

Low 🟩

Support for Bone Formation

Estrogen restrains bone breakdown; progesterone acts on the other side of the remodelling cycle, stimulating osteoblasts (the cells that build new bone) through their own progesterone receptors. This gives a mechanistic reason to expect additive benefit rather than redundancy. The supporting human evidence is a pooled analysis and a set of small trials, not a fracture-endpoint trial, and the one randomized test of the proposed mechanism — a three-month trial of progesterone alone — found no change in sclerostin (a protein that suppresses bone formation). The signal is biologically coherent and clinically unproven.

Magnitude: Pooled data indicate that adding progesterone to estrogen or another bone-preserving therapy contributes roughly 0.68% additional spinal bone mineral density (BMD — a measure of bone mass per area) per year; women whose cycles were ovulation-disturbed more than about 31% of the time lost close to 1% of spinal density per year.

Short-Term Cardiovascular Safety Markers

A three-month randomized placebo-controlled trial in 133 healthy early postmenopausal women measured endothelial function (how well blood vessels dilate, an early marker of vascular health) as a primary outcome and found no change, alongside no change in blood pressure, weight, waist circumference, fasting glucose, inflammation, or coagulation markers. This supports short-term vascular safety of progesterone used alone. It is a surrogate-marker trial of three months’ duration and says nothing about heart attacks or strokes over years.

Magnitude: Forearm blood flow response was 487% above baseline on progesterone versus 408% on placebo (difference not significant, 95% CI −74 to 232); high-sensitivity C-reactive protein (hs-CRP, a general marker of inflammation), albumin, D-dimer, blood pressure, and Framingham risk score were unchanged versus placebo.

Control of Heavy or Erratic Perimenopausal Bleeding

In perimenopause, estrogen levels swing erratically high while ovulation becomes intermittent, leaving the uterine lining over-stimulated and under-opposed; heavy and unpredictable flow follows. Cyclic progesterone dosed for the second half of the cycle is used to re-impose an orderly shedding pattern. The rationale is strong and clinical use is long-standing, but the controlled evidence for progesterone specifically — as opposed to synthetic progestins or the levonorgestrel intrauterine device — is thin.

Magnitude: Not quantified in available studies.

Mood and Daily-Function Effects ⚠️ Conflicted

Allopregnanolone is calming in most people and mood-lowering in a subset, producing genuinely opposite outcomes from the same molecule. Randomized trial data show no average worsening of depression scores and a measurable improvement in how much menopausal symptoms interfere with daily life, while challenge studies and clinical experience document a minority who feel flat, irritable, or low. Whether an individual falls into the responsive or the sensitive group appears to track prior history of premenstrual mood disturbance, and cannot currently be predicted from a blood test.

Magnitude: In the four-month perimenopausal randomized trial, perimenopause-related life interference improved significantly on progesterone (P = 0.017; P is the probability that a result of that size arose by chance) with no increase in depression scores versus placebo.

Speculative 🟨

Neuroprotection and Brain Aging

Progesterone receptors are expressed throughout the brain, allopregnanolone promotes myelin repair in animal models, and both hormones fall sharply at menopause — a combination that has generated substantial interest in progesterone as a brain-aging intervention. The countervailing evidence is important: two large randomized trials of progesterone in acute traumatic brain injury, where the animal data were strongest, both failed, and a Cochrane review found no mortality or disability benefit. The basis for the longevity-relevant claim is therefore mechanistic and observational only, with the one rigorous human test of the neuroprotection hypothesis having come out negative in a different clinical setting.

Restoration of an Ovulatory Hormonal Pattern as a Longevity Strategy

The proposition that years of low-progesterone, ovulation-disturbed cycles impose a cumulative cost on bone and vascular tissue — and that correcting them earlier changes long-run outcomes — is an explicit, testable hypothesis advanced from menstrual-cycle research. Supporting evidence is observational and mechanistic: associations between ovulatory disturbance and bone loss, and the physiological plausibility of the bone-formation pathway. No trial has followed people treated on this basis to a hard outcome, and no mortality or healthspan data exist.

Support of Breathing During Sleep

Progesterone is a respiratory stimulant, and the rise in obstructive sleep apnea after menopause has prompted the suggestion that replacing it might help. The available human data are old, small, and inconsistent, with some studies showing modest improvement in breathing indices and others none. The basis for this item is mechanistic and from isolated reports, not controlled evidence.

Benefit-Modifying Factors

  • Genetic variation in metabolizing enzymes: The proportion of a dose converted to allopregnanolone depends on 5α-reductase (encoded by SRD5A1, the enzyme that also converts testosterone to its more potent form) and aldo-keto reductase enzymes (the AKR1C family, which perform the final step to the active neurosteroid). Faster converters get more sedation and more sleep benefit from the same dose; slower converters may need a higher dose for the same effect. CYP3A4 and CYP3A5 (liver enzymes that clear a large share of all medications) variants shift clearance in either direction.
  • Progesterone receptor variants: The PGR +331G/A polymorphism (a common single-letter change in the progesterone receptor gene that alters the balance of receptor isoforms produced) has been studied for its influence on endometrial response and on hormone-therapy clot risk. It is not routinely tested and its clinical weight is unsettled, but it is the plausible explanation for why endometrial response to a standard dose is not uniform.
  • Baseline hormone levels: Benefit is largest where the deficit is largest. Someone with a mid-luteal progesterone (the luteal phase is the second half of the cycle, after ovulation; mid-luteal means about a week after it, when levels peak) above 10 ng/mL and regular ovulatory cycles has little to gain; someone with anovulatory cycles (cycles in which no egg is released), premature ovarian insufficiency (loss of ovarian function before age 40), or established postmenopause has the most to gain. Baseline estradiol matters equally — progesterone opposing high estrogen behaves differently from progesterone in a low-estrogen setting.
  • Baseline symptom burden and sleep quality: The sleep benefit was demonstrated in disturbed sleep and was absent in undisturbed sleep. Vasomotor benefit scales with baseline symptom frequency. Those starting from a good baseline see proportionally less.
  • Sex-based differences: Nearly the entire clinical evidence base is in women, and within that, in peri- and postmenopausal women. In men, progesterone circulates at low levels, is a precursor to other steroids, and has mild antiandrogenic activity through 5α-reductase inhibition; there is no controlled evidence of health or longevity benefit, and the antiandrogenic action creates a plausible route to harm. In transgender women, a systematic review of progestogen use in gender-affirming therapy found the evidence insufficient to establish benefit.
  • Pre-existing health conditions: Prior hysterectomy removes the single best-established indication, since there is no uterine lining to protect. Obesity raises the volume of distribution of a fat-soluble hormone and raises endogenous estrogen from fat tissue, altering both dosing and the endometrial risk being managed. Untreated thyroid disease, insulin resistance, and chronic stress physiology all suppress ovulation and blunt the response to any hormonal intervention.
  • Age and time since the final menstrual period: Benefit for symptoms and for the vascular and bone markers has been shown mainly in the first decade after the final period; the trials in this review enrolled women 1–11 years past it. Applying those findings to a woman two decades past menopause extrapolates beyond the tested population, and the sedative effect is generally more pronounced with advancing age.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Sedation, Dizziness, and Residual Next-Day Impairment

The most common and most predictable adverse effect follows directly from allopregnanolone’s action on GABA-A receptors, and it is dose-related. It appears within an hour of dosing, which is precisely why the standard instruction is to take the dose at bedtime and not to drive after taking it. In randomized trials it accounted for most treatment discontinuation, though the discontinuation rate was not dramatically higher than placebo. It is fully reversible on stopping and often diminishes over the first weeks of use.

Magnitude: In a 12-week randomized trial of 300 mg at bedtime, 9% of participants discontinued for adverse events — 8 of 75 on progesterone versus 4 of 58 on placebo — with no serious cases.

No Endometrial Protection from Transdermal Creams

The most consequential risk associated with progesterone is not a side effect of the hormone but a failure mode of a delivery route. Transdermal creams produce blood levels far below those achieved by oral or vaginal dosing and do not oppose estrogen at the uterine lining. Anyone using estrogen with a cream in the belief that the uterus is protected is in effect on unopposed estrogen, with the hyperplasia risk documented above. This is established by systematic review and is the single most important practical distinction in the whole topic.

Magnitude: Systematic review found that oral micronized progesterone at 200 mg/day for 12–14 days per month protects the endometrium for up to 5 years, and vaginal dosing at 45–100 mg regimens for 3–5 years off-label, while transdermal micronized progesterone provides no endometrial protection at any studied dose.

Medium 🟥 🟥

Endometrial Cancer Risk with Long-Term Combined Use ⚠️ Conflicted

Oral micronized progesterone prevents hyperplasia on a three-year randomized tissue endpoint, but the largest cohort to examine cancer endpoints found the opposite signal over longer follow-up: users of estrogen with micronized progesterone developed more endometrial cancer than never-users, and the excess widened with duration of use. The proposed explanation is potency — the standard 200 mg cyclic regimen opposes estrogen less completely than a synthetic progestin does, so a residual proliferative stimulus accumulates across years rather than being fully switched off each cycle. The evidence is observational and open to confounding by indication (the possibility that the reason a treatment was chosen, rather than the treatment itself, explains the outcome), but it is the reason a randomized trial with endometrial pathology as a co-primary endpoint is now running. Anyone on combined therapy beyond five years is operating in the range where the randomized tissue data and the cohort cancer data disagree.

Magnitude: Ever use of estrogen plus micronized progesterone carried a hazard ratio (HR — the ratio of the rate of events in treated versus untreated groups over time) of 1.80 (95% CI 1.38–2.34) for endometrial cancer versus never-use, rising from 1.39 (0.99–1.97) at five years or less to 2.66 (1.87–3.77) beyond five years; preparations containing other progesterone derivatives showed no excess (0.79, 0.60–1.05).

Breast Cancer Risk with Use Beyond About Five Years

The reassuring cohort finding of a neutral breast signal applies to shorter durations. The systematic review of the same literature concluded there is limited evidence that combined therapy with oral micronized progesterone used for more than five years is associated with increased breast cancer risk, and the underlying data are observational throughout. Progesterone’s relative advantage over other progestogens appears real; an absolute guarantee of neutrality over a decade or more does not exist. Anyone using combined therapy long-term is operating beyond the tested duration.

Magnitude: Estrogen plus progesterone carried a relative risk of 1.00 (95% CI 0.83–1.22) versus never-use in cohort data covering an average of 8.1 postmenopausal years of follow-up, against 1.69 (1.50–1.91) for estrogen plus other progestogens; the corresponding systematic review found no excess up to 5 years and limited evidence of excess beyond it.

Mood Disturbance in Susceptible Individuals

A minority experience low mood, irritability, tearfulness, or emotional flatness rather than calm. The mechanism is the same neurosteroid pathway that produces the benefit: allopregnanolone’s effect at GABA-A receptors is biphasic, and some people respond to intermediate concentrations with low mood instead of calm. This is the same biology implicated in premenstrual dysphoric disorder (severe mood symptoms in the days before menstruation), and a personal history of it is the best available predictor. The effect is dose-related and reverses on withdrawal.

Magnitude: Randomized trials show no average increase in depression scores versus placebo, so the effect is confined to a susceptible subgroup rather than being a population-level risk; among that subgroup it is reported at a frequency comparable to the mood effects of synthetic progestins.

Cyclic Bleeding, Breast Tenderness, and Bloating

Cyclic dosing deliberately induces withdrawal bleeding, which is the intended mechanism of endometrial protection but is frequently unwelcome in postmenopause. Breast tenderness and a bloated feeling are common in the first cycles and reflect the transient estrogen up-regulation that progesterone can produce before settling. Unscheduled spotting on continuous regimens is common early and warrants evaluation if it persists beyond six months, because it cannot be distinguished from pathology on symptoms alone.

Magnitude: The cyclic 200 mg for 12–14 days regimen produces scheduled withdrawal bleeding in the majority of women with an intact uterus, whereas continuous daily 100 mg dosing usually results in no bleeding after the first 6–12 months.

Nausea and Gastrointestinal Upset

Nausea, sometimes with vomiting or abdominal discomfort, appears among the adverse reactions listed in United States prescribing information for micronized progesterone capsules and is, after sedation, the most frequent tolerability complaint in practice. The mechanism is the oil-suspended capsule and the large first-pass load on the liver rather than any specific action of the hormone on the gut, which is why taking the dose with a small amount of food and at bedtime blunts it substantially. It is dose-related, most prominent in the first weeks, and generally settles with continued use rather than requiring discontinuation. Vaginal administration avoids it almost entirely, since the gastrointestinal and hepatic exposure is bypassed.

Magnitude: Nausea is reported at a frequency comparable to abdominal bloating and breast tenderness in the labelled trials of oral micronized progesterone, and well below that of somnolence, which remains the dominant reason for stopping.

Allergic Reaction to Capsule Excipients

Micronized progesterone capsules marketed in the United States, including the originator brand and several generics, suspend the hormone in peanut oil and carry an explicit contraindication in peanut allergy. This is an excipient problem rather than a hormone problem, and it is solvable — several non-United States products and some compounded preparations use sunflower or olive oil instead — though an unrecognized peanut exposure can produce a severe reaction.

Magnitude: Peanut allergy affects roughly 1–2% of adults in Western populations, all of whom must avoid peanut-oil-based capsules entirely; sunflower-oil formulations remove the exposure completely.

Low 🟥

Small Reduction in High-Density Lipoprotein Cholesterol

Progesterone modestly lowers high-density lipoprotein cholesterol (HDL, the cholesterol fraction inversely associated with cardiovascular risk). This was the only lipid change detected in an otherwise neutral randomized trial, and the investigators judged it not clinically important because the composite cardiovascular risk score did not change. It is nonetheless a real directional effect worth tracking in anyone whose lipid profile is borderline.

Magnitude: HDL cholesterol fell by 0.14 mmol/L (approximately 5 mg/dL) relative to placebo over three months on 300 mg nightly, with total cholesterol, low-density lipoprotein cholesterol, and triglycerides unchanged.

Headache and Migraine Around Hormone Withdrawal

Falling hormone levels trigger migraine in susceptible people, and cyclic regimens create a deliberate monthly fall. Headache is a recognized adverse effect in product labelling, and clinicians working with cyclic dosing steer those with migraine with aura (visual or sensory warning symptoms preceding the headache) toward daily rather than cyclic use for this reason.

Magnitude: Withdrawal-triggered headache is reported more frequently on start–stop cyclic regimens than on continuous daily dosing, which is the basis for switching susceptible users to daily administration.

Hepatic Considerations with Oral Dosing

Oral dosing routes the entire dose through the liver first. In healthy people this is merely inefficient, but in active liver disease it is a labelled contraindication, and cholestatic jaundice (impaired bile flow causing yellowing of the skin and eyes) is listed among rare adverse effects for progestogens generally. A prior history of hormone-associated cholestasis in pregnancy is a specific caution.

Magnitude: Only a small fraction of an oral dose survives first-pass hepatic metabolism to reach the circulation, which is why oral doses of 100–300 mg are needed to reproduce luteal-phase blood levels that the ovary achieves with roughly 25 mg per day of endogenous output.

Speculative 🟨

Probable Dementia Carried Over from the Progestin Class Boxed Warning

United States prescribing information for micronized progesterone capsules carries the estrogen-plus-progestin class boxed warning, which includes an increased incidence of probable dementia in women aged 65 and older. That warning rests on the Women’s Health Initiative Memory Study substudy, which tested conjugated equine estrogens with medroxyprogesterone acetate and never enrolled anyone taking progesterone, so the label applies a class inference rather than a measured finding. No trial has assessed dementia incidence on progesterone specifically, and the direction of any progesterone effect is unresolved: allopregnanolone promotes myelin repair in animal models, while the two large trials of progesterone in traumatic brain injury failed. The basis for this item is therefore extrapolation from a different progestogen plus mechanistic reasoning, not controlled evidence in progesterone users.

Meningioma Signal Attaching to the Progestogen Class

Several synthetic progestogens are now established causes of meningioma (a usually benign tumour of the membranes covering the brain) with prolonged use, and the finding has driven regulatory action in Europe. A national case-control study covering 18,061 women who had intracranial surgery for meningioma and 90,305 matched controls found substantial excess risk for medrogestone, injectable medroxyprogesterone acetate, promegestone, cyproterone acetate, nomegestrol acetate, and chlormadinone acetate — and specifically no excess risk for progesterone itself, dydrogesterone, or levonorgestrel intrauterine systems. The residual concern for progesterone is therefore an inference from the class, not an observed signal, and the best available evidence argues against it.

Suppression of Endogenous Hormones and Antiandrogenic Effects in Men

Exogenous steroid administration suppresses the pituitary signals that drive endogenous production, and progesterone’s mild 5α-reductase inhibition and antiandrogenic activity give a mechanistic route to reduced libido, gynecomastia (breast tissue growth in men), and blunted testosterone signalling. No controlled trial has evaluated progesterone supplementation in healthy men for health or longevity purposes, so this rests on mechanism and isolated reports rather than data.

Insulin Resistance at Exposures Above Natural Levels

Progesterone at high concentrations reduces insulin sensitivity in laboratory and animal models, and the physiological luteal phase is mildly insulin-resistant. The systematic review of clinical data found no adverse glucose effect at therapeutic doses, so this concern applies only to exposures above the tested range and remains mechanistic — noting again that the review in question comes from the menopause-society-affiliated group whose members earn their income from providing this therapy.

Risk-Modifying Factors

  • Genetic variation in metabolizing enzymes: Rapid conversion to allopregnanolone via 5α-reductase (SRD5A1) and the AKR1C enzymes raises sedation and low-mood risk at any given dose; slow clearance through CYP3A4 and CYP3A5 (the liver enzymes handling most drug metabolism) does the same by prolonging exposure. These are not routinely genotyped, so the practical proxy is a cautious starting dose and observation of the response.
  • Progesterone receptor variants: The PGR +331G/A variant has been examined for its influence on hormone-therapy clot risk and on endometrial response, and is the most likely genetic explanation for why some women bleed unpredictably on standard regimens. Evidence remains preliminary and does not currently justify testing.
  • Baseline biomarker levels: Baseline HDL cholesterol determines whether the small HDL reduction matters at all — irrelevant at 70 mg/dL, worth watching at 40 mg/dL. Baseline endometrial thickness on ultrasound determines how much protection is needed and how urgently bleeding must be investigated. Baseline liver enzymes identify anyone for whom oral dosing is inadvisable.
  • Sex-based differences: Effectively all safety data derive from women. In men, the antiandrogenic and pituitary-suppressive risks described above have no counterpart in the female safety profile, so the female evidence base cannot be used to reassure male users. In transgender women taking estrogen, the systematic review of gender-affirming progestogen use found the evidence insufficient to characterize either benefit or risk.
  • Pre-existing health conditions: Active liver disease, undiagnosed vaginal bleeding, known or suspected breast cancer, current or past arterial thromboembolic disease, and peanut allergy (for peanut-oil capsules) are the labelled contraindications. A history of premenstrual dysphoric disorder or of depression triggered by hormonal contraception predicts the mood risk. Obesity, smoking, and clotting disorders raise the background risk that any hormone therapy is added to, even where progesterone itself appears clot-neutral.
  • Age and time since the final menstrual period: Sedation, falls, and next-morning impairment become more consequential with age, particularly alongside other centrally acting medications. Starting hormone therapy more than a decade past the final period moves outside the population in which the safety data were generated, and the risk-benefit balance shifts accordingly.

Key Interactions & Contraindications

  • Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St John’s wort): Caution; these accelerate clearance and can lower progesterone exposure enough to lose endometrial protection during estrogen therapy — the clinical consequence being unopposed estrogen and hyperplasia risk. Mitigation is a higher progesterone dose with endometrial ultrasound surveillance, or switching the endometrial protection to a levonorgestrel intrauterine device.
  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Monitor; these raise exposure and amplify sedation and dizziness. Mitigation is a dose reduction of 50% with re-titration after the interacting drug is stopped.
  • Central nervous system depressants (benzodiazepines such as lorazepam, “Z-drugs” such as zolpidem, opioids such as oxycodone, gabapentinoids — nerve-pain and anxiety drugs such as gabapentin and pregabalin — and antihistamines such as diphenhydramine): Caution; additive sedation with a real risk of next-morning impairment and falls. Mitigation is separating dosing where possible, taking progesterone only at bedtime, and reducing the co-administered sedative first.
  • Alcohol: Caution; alcohol and allopregnanolone act on overlapping GABA-A sites, so evening drinking compounds sedation and fragments the second half of the night, undercutting the sleep benefit being sought. Mitigation is separating alcohol from the dose by several hours and keeping evening intake to a single unit or none on dosing nights.
  • Estrogen therapy (oral or transdermal estradiol, conjugated equine estrogens): Caution; this is the intended pairing rather than an adverse interaction, but it is not optional in the other direction — estrogen taken with an intact uterus and without adequate progestogen cover produces endometrial hyperplasia and, with time, endometrial cancer. Mitigation is matching progesterone dose and duration to the estrogen dose and maintaining it for as long as the estrogen continues.
  • Supplements with additive sedative or GABA-ergic effects (valerian, kava, magnesium glycinate at high doses, melatonin, cannabidiol, L-Theanine): Monitor; additive drowsiness. Mitigation is to introduce one agent at a time and to lower the sedative supplement rather than the hormone if the endometrial indication is the priority.
  • Supplements affecting steroid metabolism or clearance (St John’s wort, high-dose curcumin, berberine, saw palmetto, diindolylmethane): Monitor; these modulate CYP3A4 or 5α-reductase and can shift exposure in either direction. Saw palmetto and progesterone both inhibit 5α-reductase, an additive antiandrogenic effect of no consequence in most women and of potential consequence in men. Mitigation is introducing one such supplement at a time against a stable progesterone dose, and adding endometrial ultrasound surveillance where a CYP3A4-inducing supplement such as St John’s wort is taken alongside estrogen therapy.
  • Anticoagulants and antiplatelet agents (warfarin, apixaban, aspirin): Monitor; no consistent pharmacokinetic interaction is established for progesterone, but any hormone therapy in someone already anticoagulated warrants a documented reason and a review of the estrogen component, which carries the clot risk.
  • Absolute contraindications: Known or suspected breast cancer or other progesterone-sensitive malignancy; undiagnosed abnormal genital bleeding; active or recent (within 12 months) arterial thromboembolic disease including myocardial infarction and stroke; active deep vein thrombosis or pulmonary embolism; severe hepatic impairment (Child-Pugh Class C, the most advanced grade of liver dysfunction); known hypersensitivity to the product, including peanut allergy for peanut-oil capsules; known or suspected pregnancy outside a fertility protocol supervised by a specialist.
  • Populations who should avoid or defer: Anyone using it as the sole endometrial protection while applying a transdermal cream; anyone with a personal history of severe hormone-triggered depression; those who must drive or work within several hours of dosing; men and transgender women outside a supervised protocol, given the absence of an evidence base; and anyone more than 10 years past the final menstrual period initiating combined therapy for the first time, where the tested population no longer applies.

Risk Mitigation Strategies

  • Bedtime-only dosing: The entire dose is taken within an hour of going to bed, and not before driving or operating machinery. This converts the sedation risk — the most common adverse effect and the leading cause of discontinuation — into the intended sleep benefit, and eliminates daytime impairment.
  • Low starting dose with slow titration: Protocols begin at 100 mg nightly, increase to 200 mg after 1–2 weeks, and reach 300 mg only where the target is vasomotor or sleep benefit rather than endometrial protection. This identifies rapid metabolizers, who get excess sedation and low mood at standard doses, before they accumulate two weeks of impaired mornings.
  • Route matched to the purpose: Oral capsules or, off-label, vaginal dosing are the routes used where endometrial protection is the goal; transdermal creams are unsuitable for that purpose regardless of the labelled strength. This directly prevents the unopposed-estrogen hyperplasia risk that follows from cream use alongside estrogen.
  • Minimum protective dose and duration maintained: Where estrogen is used with an intact uterus, the protective threshold is at least 200 mg for 12–14 days per cycle, or 100 mg daily continuously, and dropping below it to manage side effects forfeits that protection unless another protective method is substituted. Reducing the dose to soften sedation is the most common way endometrial protection is silently lost.
  • Oil base verified before the first dose: The excipient list identifies whether the capsule is peanut-oil based, and a sunflower-oil formulation is the substitute where peanut allergy is present or unknown. This removes an anaphylaxis risk entirely at zero cost.
  • Scheduled endometrial surveillance: For anyone on estrogen with a uterus, surveillance consists of a transvaginal ultrasound at baseline plus investigation of any unscheduled bleeding that persists beyond six months on a continuous regimen, or any bleeding outside the expected withdrawal window on a cyclic regimen. Hyperplasia is asymptomatic until it bleeds, and bleeding is the only early warning available.
  • Daily rather than cyclic dosing in migraine with aura: Deliberate monthly withdrawal is a migraine trigger; continuous dosing avoids the fall in hormone levels that provokes it.
  • A review point rather than an open-ended prescription: The reason for continuing is reassessed at 12 months and then annually, with explicit attention to duration beyond five years, where both the breast and the endometrial cancer evidence weakens. This forces a conscious decision at the point where the evidence base stops supporting the default.
  • Separation of sedating agents: Overlapping sedatives — sleep medications, antihistamines, evening alcohol — are reduced or stopped before progesterone is added rather than after, and reassessed after four weeks. This prevents the additive impairment and falls that account for most serious harm in older users.

Therapeutic Protocol

  • Standard endometrial-protection regimen: The regimen with the strongest evidence, used by menopause specialists worldwide, is 200 mg of oral micronized progesterone at bedtime for the first 12–14 days of each 28-day cycle alongside estrogen, or 100 mg nightly continuously. The cyclic version produces predictable monthly bleeding; the continuous version usually produces none after the first year.
  • Symptom-directed monotherapy: Where estrogen is unsuitable or unwanted, 300 mg at bedtime has been used in randomized trials for hot flushes, night sweats, and sleep. This approach was developed and tested principally by Jerilynn Prior’s group at the Centre for Menstrual Cycle and Ovulation Research at the University of British Columbia, which also popularized cyclic dosing at 300 mg for 14 days per cycle in perimenopause.
  • Competing approaches, presented as alternatives: Three protocols are in active use and none is established as correct. The conventional menopause-society approach treats progesterone as endometrial protection only, at the lowest dose that achieves it, for the shortest duration consistent with symptom control — an approach set out by professional bodies whose member clinicians derive their income from providing this care. The cycle-physiology approach treats progesterone as an independent hormone worth restoring in its own right, uses higher doses, and starts in perimenopause rather than after the final period. The compounded-bioidentical approach, associated with practitioners including Jonathan Wright and promoted heavily by compounding pharmacies, uses custom creams and lozenges at individualized doses — an approach whose commercial backers profit directly from it and whose products have not demonstrated endometrial protection.
  • Best time of day: Bedtime, without exception for oral dosing. Blood levels peak 1–3 hours after the dose, and the sedative effect is at its maximum exactly then. Splitting a dose across the day converts the main benefit into the main side effect.
  • Half-life and dose splitting: With levels peaking at 1–3 hours and falling steeply thereafter, oral progesterone does not sustain 24-hour luteal-range levels from a single dose, which is one argument advanced for the 300 mg bedtime dose. Splitting into morning and evening doses is not standard and is generally avoided because it produces daytime sedation; where a sustained level is genuinely required, vaginal dosing is the alternative used in fertility medicine.
  • Vaginal dosing as an off-label alternative: Vaginal administration exploits a uterine first-pass effect, achieving high endometrial concentrations with low blood levels and therefore much less sedation. Regimens of 45–100 mg have been used for endometrial protection off-label. It is the option for those who cannot tolerate oral sedation but need uterine cover.
  • Genetic considerations in dose choice: Variation in 5α-reductase (SRD5A1) and the AKR1C enzymes determines how much allopregnanolone a given dose generates, and CYP3A4/CYP3A5 variation determines how fast it clears. Neither is routinely tested, so titration from a low dose serves as the practical substitute. There is no validated pharmacogenetic test guiding progesterone dosing.
  • Sex-based differences in dosing: All established regimens are female regimens. No validated dose exists for men or for transgender women; where progesterone is used in gender-affirming care, doses of 100–200 mg nightly have been reported, but a systematic review found the evidence insufficient to support any specific regimen.
  • Age-related considerations: Older users are more sensitive to the sedative effect and more vulnerable to its consequences, and protocols past age 65 accordingly start at 100 mg and increase only if needed. Those more than 10 years past the final menstrual period fall outside the population studied in the trials cited here, which is itself a reason to individualize rather than default.
  • Baseline biomarker influences on response: Mid-luteal progesterone, estradiol, and follicle-stimulating hormone (FSH — the pituitary signal that rises as ovarian function declines) determine where in the transition someone sits and therefore which regimen fits. Cyclic dosing suits a still-cycling perimenopausal pattern; continuous dosing suits established postmenopause.
  • Pre-existing conditions influencing response: Prior hysterectomy removes the endometrial indication entirely, leaving only symptom-directed use. Obesity raises both the distribution volume and background estrogen exposure, favouring the higher end of dosing. Untreated hypothyroidism, insulin resistance, and chronic under-eating suppress ovulation, and protocols address them alongside rather than after any hormonal intervention.

Discontinuation & Cycling

  • Lifelong or time-limited: Neither is established. Where progesterone accompanies estrogen, it continues for as long as the estrogen does, so the duration question is really a question about estrogen. Where it is used alone for symptoms, use is typically time-limited to the symptomatic years, and the weakening of the breast cancer evidence beyond five years is the main reason to revisit the decision annually rather than to continue indefinitely by default.
  • Withdrawal effects: Randomized trial data specifically examined whether stopping causes rebound hot flushes and found no withdrawal rebound after progesterone was discontinued, which distinguishes it from the well-documented symptom rebound seen when estrogen is stopped abruptly. Sleep quality typically returns to its pre-treatment baseline within days rather than deteriorating below it.
  • Tapering: No taper is pharmacologically required, and trials have stopped it outright without incident. A gradual step-down — 300 mg to 200 mg to 100 mg over several weeks — is nonetheless commonly used for those who value the sleep effect, purely to make the change less noticeable rather than for safety.
  • Cycling for continued efficacy: There is no evidence that tolerance develops to progesterone’s endometrial or vasomotor effects, so cycling is not required to maintain efficacy. Cyclic dosing is used for a different reason entirely — to reproduce the natural luteal pattern and produce orderly shedding of the uterine lining — and the choice between cyclic and continuous dosing is driven by bleeding preference and migraine history, not by tolerance.
  • Stopping while continuing estrogen: This is the one discontinuation pattern that carries real risk. Anyone with an intact uterus who stops progesterone but continues estrogen returns to unopposed estrogen exposure, and the hyperplasia rates from the three-year trial apply from that point onward.

Sourcing and Quality

  • Approved oral capsules are the reference product: Micronized progesterone capsules are available as an approved prescription medicine — marketed as Prometrium and as generics in North America, and as Utrogestan in Europe and much of the world — manufactured to pharmacopoeial standards with verified content and dissolution. A combined estradiol-and-progesterone capsule (Bijuva) is also approved. Approved products are the only preparations with demonstrated endometrial protection.
  • Check the oil base and excipients: United States capsules suspend the hormone in peanut oil; several European and Canadian products use sunflower oil. This is stated on the label and determines suitability for anyone with peanut allergy. Capsule shells are gelatin-based, which is relevant for vegetarian and vegan users.
  • Compounded preparations require a reputable pharmacy: Compounding pharmacies produce creams, lozenges, and custom-strength capsules that are not approved products and are not subject to the same batch testing. Where compounding is genuinely necessary — an excipient allergy, an unavailable strength — the relevant markers of quality are accreditation by the Pharmacy Compounding Accreditation Board, registration as an outsourcing facility under section 503B (which subjects the pharmacy to manufacturing-standard inspection), and willingness to supply potency assay results for the batch.
  • Over-the-counter creams are a different product class: Independent laboratory testing found that progesterone creams generally contain the progesterone they claim, so content is not usually the problem. The problem is that the delivered dose does not protect the uterine lining or preserve bone density, whatever the label implies. Products labelled as “wild yam” extract are a further step removed — the human body does not convert diosgenin from yam into progesterone, so such products contain none unless progesterone has been added.
  • Third-party testing for any non-prescription product: The markers of adequate testing are a certificate of analysis identifying the batch, an independent laboratory rather than an in-house assay, and testing for both potency and contamination. The absence of a batch-specific certificate is the practical disqualifier.

Practical Considerations

  • Time to effect: Sleep effects appear on the first night. Vasomotor benefit builds over 4–12 weeks, with the randomized trials measuring their primary outcome at week 12. Endometrial protection is exerted from the first treated cycle. Bone effects, where present, take 6–12 months to register on a density scan.
  • Common pitfalls: Taking the dose in the morning and then feeling impaired all day; assuming a transdermal cream provides uterine protection; reducing the dose to soften sedation and dropping below the protective threshold; treating progesterone and progestin evidence as interchangeable in either direction; expecting an over-the-counter cream to reproduce prescription-strength effects; and stopping progesterone while continuing estrogen.
  • Regulatory status: Oral micronized progesterone is an approved prescription medicine for endometrial protection during estrogen therapy and for secondary amenorrhea (absent periods not caused by pregnancy). Use for sleep, for hot flushes as monotherapy, and by the vaginal route for endometrial protection are all off-label — legal, common, and evidence-supported to varying degrees, but not label-sanctioned. Compounded preparations are not approved products at all. In much of Europe, regulators have recently restricted several synthetic progestogens over meningioma risk, without applying those restrictions to progesterone.
  • Cost and accessibility: Generic oral micronized progesterone is inexpensive — typically in the range of US$15–40 per month without insurance — and widely stocked. Compounded creams and lozenges commonly cost two to four times that and are rarely covered. Cost is not a meaningful barrier to the approved product, which makes the price premium on compounded alternatives difficult to justify on anything other than a specific formulation need.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Bedtime dosing shortens time to fall asleep and reduces time awake during the night, with the effect appearing specifically when sleep is disturbed rather than when it is already sound. The practical corollaries are to dose within an hour of lights-out, to avoid stacking it with other sleep agents until the response is known, and to expect no benefit — and possibly unnecessary sedation — if sleep is already good.
  • Nutrition: Direct on absorption, indirect on production. Absorption of a fat-soluble steroid improves when taken with food containing fat, so a small fat-containing evening snack raises exposure from the same dose, while taking it on an empty stomach lowers and destabilizes it. Sustained energy deficiency and very low body fat suppress ovulation and therefore endogenous progesterone, so chronic under-eating works against the same endpoint the hormone is being used to reach. Grapefruit juice inhibits CYP3A4 and raises exposure enough to increase sedation.
  • Exercise: Indirect. There is no evidence that progesterone blunts training adaptation or hypertrophy (muscle growth) — a real concern with some antiandrogenic agents but not established here. The meaningful interaction runs the other way: high training volume combined with inadequate energy intake is a leading cause of ovulatory disturbance and low endogenous progesterone in younger women, and resistance training is the necessary partner to any hormonal strategy aimed at bone. Timing relative to training is irrelevant given bedtime dosing; scheduling hard morning sessions on days when residual next-morning sedation is present is worth avoiding.
  • Stress management: Direct and bidirectional. Sustained stress suppresses the pituitary signals driving ovulation, lowering endogenous progesterone, while progesterone’s metabolite allopregnanolone dampens the stress response through GABA-A receptors and has been shown to modulate stress biomarkers. This means stress reduction and progesterone act on the same axis from opposite ends, and it also means an unaddressed stress load will keep regenerating the deficit that supplementation is patching. Evening practices that lower arousal — breathwork, light exposure control, a consistent wind-down — compound with the bedtime dose rather than duplicating it.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes where in the menopausal transition someone sits, documents the state of the uterine lining if estrogen is being used alongside, and captures the metabolic and liver markers that the therapy could plausibly move. Baseline testing is most informative when drawn in the morning after an overnight fast, and — for anyone still cycling — with the progesterone sample timed to roughly one week after presumed ovulation.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Progesterone (serum) Mid-luteal >10 ng/mL, with 15–20 ng/mL as the functional target in cycling women Confirms whether ovulation is occurring and quantifies the deficit Meaningless if drawn at a random cycle day. Conventional mid-luteal reference intervals start near 1.8 ng/mL and treat anything above roughly 3 ng/mL as ovulatory, far beneath the functional target. Oral dosing raises metabolites more than parent hormone, so on-treatment levels understate effect and are not used to titrate
Estradiol (E2) 30–100 pg/mL on therapy; interpretation depends entirely on the estrogen dose Sets the context progesterone is opposing; unopposed estrogen is the risk being managed E2 is estradiol, the main estrogen of the reproductive years. Draw with progesterone. Conventional postmenopausal reference ranges sit below roughly 30 pg/mL, describing the untreated state rather than the on-therapy target. Perimenopausal values swing widely, so a single reading is not diagnostic
Follicle-stimulating hormone (FSH) <25 IU/L before menopause; >25–30 IU/L indicates the transition is well advanced Locates the user in the menopausal transition and guides cyclic versus continuous dosing Best drawn on day 3 of a cycle in those still menstruating. Conventional reference intervals are far wider — roughly 3.5–12.5 IU/L in the first half of a cycle and roughly 26–135 IU/L after menopause — so a result inside “normal” says little about where the transition stands
Endometrial thickness (transvaginal ultrasound) <4–5 mm in postmenopause The only direct measure of whether endometrial protection is working Baseline before starting estrogen, then only if unscheduled bleeding occurs. Not needed for progesterone monotherapy without estrogen
Lipid panel including HDL cholesterol HDL >50 mg/dL in women, >40 mg/dL in men; triglyceride-to-HDL ratio <2 Progesterone produces a small HDL reduction that matters only if HDL is already low 12-hour fast. Conventional cut-offs are lower (HDL >40 mg/dL for women), so a “normal” result can still represent a meaningful fall
TSH and free T4 TSH 0.5–2.0 mIU/L; free T4 in the upper half of the reference range Progesterone therapy has been shown to raise free thyroxine, which can alter dose requirements in treated thyroid disease TSH is thyroid-stimulating hormone, the pituitary signal to the thyroid; free T4 is free thyroxine, the unbound circulating thyroid hormone. Draw before the morning thyroid medication dose. Conventional TSH ranges extend to 4.5 mIU/L, well above the functional target
HbA1c and fasting insulin HbA1c <5.4%; fasting insulin <6 μIU/mL Confirms the expected metabolic neutrality and detects drift Fasting for insulin. Pair with fasting glucose to compute insulin resistance indices. Conventional labs flag HbA1c only at 5.7% and fasting insulin only above roughly 25 μIU/mL, so a “normal” result can sit well above the functional target
Liver enzymes (ALT, AST) and bilirubin ALT <25 U/L in women, <30 U/L in men Oral dosing is metabolized hepatically and is contraindicated in active liver disease ALT is alanine aminotransferase and AST is aspartate aminotransferase, enzymes released into blood when liver cells are damaged. Conventional upper limits near 40 U/L are set from populations with a high prevalence of fatty liver and are too permissive
Complete blood count with ferritin Ferritin 50–100 ng/mL Heavy perimenopausal bleeding, the problem cyclic dosing often addresses, depletes iron before hemoglobin falls Ferritin rises with inflammation, so pair with hs-CRP to interpret a normal-looking result. Conventional lower limits run as low as 15 ng/mL, far beneath the functional floor
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L General inflammatory marker; randomized data show it should not move on progesterone Invalid within two weeks of infection or injury. Conventional reporting treats anything below 3.0 mg/L as low risk, three times the functional target

Ongoing monitoring is lighter than the baseline panel. A reasonable cadence is symptom review at 4 weeks, a first laboratory recheck at 3 months covering lipids, thyroid, and liver enzymes, and then every 6–12 months thereafter, with breast imaging on the standard age-appropriate schedule and endometrial ultrasound only if unscheduled bleeding occurs. Duration of use is formally revisited at 12 months and annually after that.

Qualitative markers often reveal more than the panel does, and are worth tracking deliberately:

  • Time to fall asleep and number of night wakings, ideally logged for two weeks before starting and again at week four
  • Next-morning alertness, and specifically whether residual sedation persists past the first hour of the day
  • Frequency and severity of hot flushes and night sweats, scored daily rather than recalled monthly
  • Mood, irritability, and emotional flatness, with particular attention in the first two cycles for anyone with a history of premenstrual mood disturbance
  • Bleeding pattern — timing, duration, and whether it falls within the expected withdrawal window
  • Breast tenderness and bloating, which typically settle after the first cycles and warrant review if they do not
  • Cognitive clarity and daytime energy, which are the endpoints most users actually care about and which no laboratory value captures

Emerging Research

  • Head-to-head trial against a synthetic progestin: NCT05586724 is a Phase 3 randomized trial of 520 women comparing micronized progesterone with norethisterone acetate in combined menopausal hormone therapy, with mammographic breast density and endometrial pathology as primary endpoints. It is the most directly relevant ongoing study for anyone weighing progesterone against a progestin, because it tests both the claimed differential breast effect and the disputed strength of endometrial protection prospectively rather than observationally.
  • Brain and heart effects across the menopausal transition: NCT07732452 is a Phase 4 study of 100 participants examining hormone therapy effects on cardiac remodelling, myocardial fibrosis, microvascular function, and cognition during the transition. It targets exactly the longevity-relevant endpoints that existing progesterone trials have not measured.
  • Progesterone in gender-affirming therapy: NCT06807580 is a Phase 2 randomized study of 40 transgender women with psychological distress as the primary outcome, addressing a use case where a systematic review has found the evidence insufficient. Results would begin to fill one of the largest evidence gaps identified in this review.
  • Endometrial protection in younger populations: NCT06357442 compares endometrial thickness in adolescents and young adults on estrogen replacement using daily oral micronized progesterone versus an etonogestrel implant, and NCT06851754 is a Phase 3 study enrolling 185 participants — 85 adolescents with premature ovarian insufficiency plus healthy controls — using lumbar spine bone density as its primary endpoint. Both test whether the adult endometrial and bone findings transfer to people who will be on therapy for decades rather than years.
  • Evidence that could strengthen the case: The bone-formation hypothesis rests on pooled data reported by Prior, 2018 suggesting progesterone adds to antiresorptive therapy (treatments that slow the breakdown of bone); the one direct test of the sclerostin mechanism, by Yang et al., 2020, found no effect on sclerostin levels and so did not support it. A randomized trial with fracture or density endpoints would move this from mechanistically plausible to established, and its absence is the reason the bone benefit is graded Low here.
  • Evidence that could weaken the case: Long-duration breast safety is the most vulnerable claim. The systematic review by Stute et al., 2018 already flags limited evidence of increased risk beyond five years, and Fournier et al., 2014 examined risk after stopping therapy in the same cohort. Longer follow-up of prospective cohorts could convert the current neutral signal into a duration-dependent one. Separately, the pharmacoepidemiological work of Roland et al., 2024 that exonerated progesterone on meningioma risk is a single national dataset; replication elsewhere is needed before the class concern can be considered closed.
  • Where the decisive trial does not exist: No randomized trial has tested progesterone against placebo with a hard cardiovascular, fracture, cognitive, or mortality endpoint. Every long-term claim in this review — favourable or unfavourable — rests on surrogate markers, observational cohorts, or extrapolation from progestin trials. That gap is the single most important feature of the evidence base.

Conclusion

Progesterone is the hormone the ovaries make after each egg release, and the version used in therapy is chemically identical to it, unlike the synthetic look-alikes that shaped older prescribing and the research behind it. Its best-supported use is protecting the lining of the uterus for people taking estrogen, where it prevents the overgrowth estrogen alone causes — though longer follow-up raises a question about whether it holds up over a decade. Creams applied to the skin do not achieve it at all — the most consequential practical point in the topic. Beyond that, controlled trials support faster, less broken sleep and relief from hot flushes and night sweats, with the sleep effect mainly in people whose sleep is already disturbed. Evidence on breast tissue, clotting, and metabolism suggests it behaves more favourably than the synthetics, though it comes from people who chose their own treatment and thins out past about five years of use. Bone and brain benefits remain plausible rather than demonstrated. The main drawback is drowsiness, which is why it is taken at night, and a minority experience low mood instead of calm.

Much of the favourable case comes from expert panels tied to menopause professional societies whose members provide this care, while compounding pharmacies profit from the very creams that fail the uterine test — financial interests on both sides of the case. No trial has followed anyone taking it long enough to see whether it changes how long or how well they live.

Top - Benefits - Risks - Protocol